TREATMENT PATTERNS AND OUTCOMES IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED IN A COMMUNITY ONCOLOGY SETTING
Author(s)
Cartwright TH1, PAN I2, Wen L3, Wadlow RC4, Rembert D5, Seal B6
1Mckesson Specialty Health, Ocala, FL, USA, 2Mckesson Specialty Health, Conroe, TX, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 4Mckesson Specialty Health, Fairfax, VA, USA, 5Mckesson Specialty Health, The Woodlands, TX, USA, 6Bayer HealthCare Pharmaceuticals, Inc., White House Station, NJ, USA
OBJECTIVES: To describe and characterize mCRC patients who received 3rd-line therapy and to investigate the association of patient outcomes and treatment patterns in a real-world community oncology network. METHODS: This retrospective study utilized data from the iKnowMed™ database and billing claims. Eligibility criteria included diagnosis of mCRC, initiation of 1st-line therapy between 1/1/2007 and 6/30/2011, and initiation of 3rd-line therapy (defined as index date) before 6/30/2012. The key outcome was overall survival (OS). Kaplan-Meier and Cox proportional hazard models were used to characterize the distribution and predictors of outcomes. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PCN12
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Oncology